Current therapy with nucleoside/nucleotide analogs for patients with chronic hepatitis B

Hepatobiliary and Pancreatic Diseases International

Volumn 5, Issue 3, 2006, Pages 350-359

  Xu, Xiao Wei ^a   Chen, Ya Gang ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Adefovir; Antivirus; Clevudine; Emtricitabine; Entecavir; Hepatitis B; Lamivudine; Telbivudine

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; CLEVUDINE; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; HEPATITIS B ANTIBODY; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; LOVIRIDE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; TELBIVUDINE; VALTORCITABINE; VIRUS DNA; ZIDOVUDINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEPATITIS B; HUMAN; MEDICAL LITERATURE; MEDLINE; NEPHROTOXICITY; NONHUMAN; REVIEW; SEROCONVERSION; VIRUS MUTATION; VIRUS REACTIVATION;

ANTIVIRAL AGENTS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B, CHRONIC; HUMANS; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33748038349     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-68.
2. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341:1256-1263.
3. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46:562-568.
4. Schiff E, Karayalcn S, Grimm I, Perrillo R, Dienstag J, Husa P, et al. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy. Hepatology 1998;28 (Suppl):388A.
5. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, et al. Histological outcome during long-term lamivudine therapy Gastroenterology 2003;124:105-117.
6. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002;36: 186-194.
7. Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000;32:635-639.
8. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119:172-180.
9. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33: 1527-1532.
10. Zoulim F, Trepo C. Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J Hepatol 1998;29:151-168.
11. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001;120:1828-1853.
12. de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003;39(Suppl 1):S3-25.
13. Lok AS, McMahon BJ; Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology 2004;39:857-861.
14. Liaw YF, Leung N, Guan R, Lau GK, Merican I; Asian-Pacific Consensus Working Parties on Hepatitis B. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol 2003;18: 239-245.
15. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B.Lamivudine Precore Mutant Study Group. Hepatology 1999;29:889-896.
16. Rizzetto M, Santantonio T, Buti M, Heathcote J, Woessner M, Daly S, et al. Benefits of extended lamivudine treatment in patients with HBeAg-negative HBV DNA positive (precore mutant) chronic hepatitis B (CHB). Hepatology 2000; 32:459A.
17. Esteban R. Clinical and histologic outcome of extended lamivudine in patients with HBeAg negative chronic hepatitis B (CHB). Hepatology 2001;34:1097A.
18. van Zonneveld M, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003;10:294-297.
19. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207-210.
20. Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, et al. Lamivudine North American Transplant Group. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001;33: 424-432.
21. Yao, FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001; 34:411-416.
22. Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996;125:705-712.
23. Dore GJ, Cooper DA, Barrett C, Goh LE, Thakrar B, Atkins M. Dual efficacy of lamivudine treatment in human immunodeficiency virus/ hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis 1999;180: 607-613.
24. CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997;349:1413-1421.
25. Zeng M, Mao Y, Yao G, Wang H, Hou J, Wang Y, et al. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology 2006;44:108-116.
26. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348:800-807.
27. Hadziyannis S, Tassopoulos N, Chang TT, Heathcote J, Kitis G, Rizzetto M, et al. Three years study of adefovir dipivoxil (ADF) demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B (CHB) patients in a long term safety and efficacy study (LTSES). J Hepatol 2004; 40 (Suppl):17
28. Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al. Behalf of the Adefovir Dipovoxil Study 435 International Investigators Group. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003;38: 1353-1355.
29. Benhamou Y, Bochet M, Thibault V, Calvez V, Fiever MH, Vig P, et al. Safety and efficacy of long-term adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in HIV infected patients. J Hepatol 2002;36(Supp 1): 138.
30. Peters MG, Hann Hw H, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126:91-101.
31. Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004;126:81-90.
32. Sung JJY, Zeuzem S, Chow WC, Chow WC, Heathcote E, Perrillo R, et al. A randomized double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment na?ve patients with chronic hepatitis B (CHB): week 52 analysis. J Hepatol 2003:38(Suppl):69.
33. de Man RA, Wolters LM, Nevens F, Chua D, Sherman M, Lai CL, et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 2001;34:578-582.
34. Colonno RJ, Rose RE, Levine SM, Pokornowski K, Plym M, Yu CF, et al. Entervir (ETV) resistance is not observed on nudeoside-na?ve subjects and is observed infrequently by week 48 in lamivudine-refractory subjects with chronic HBV infection. J Hepatol 2005;43 (Suppl):173.
35. Leung N, Gish RG, Wanf C, Corey L, Sacks S, Fried M, et al. A randomized, double-blind comparison of 3 doses of emtrictabine in patients with chronic hepatitisB given 48 weeks of treatment. Hepatology 2001;34:349A.
36. Wang C, Corey L, Leung N, Gish R, Rigney A, Fang L, et al. Antiviral activity of 48 weeks of emtricitabine treatment in patients with HBeAg negative/HBV DNA positive chronic hepatitis B. Hepatology 2001;34:323A.
37. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al. Telbivudine Phase II Investigator Group. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528-536.
38. Han SH, Leung NW, Teo EK, Tong M, Wong F, Hann HW et al. Results of a one-year international phase II b trial of LdT, and LdT plus lamivudine, inpatients with chronic hepatitis B. J Hepatol 2004;40(Suppl): 16.
39. Peek SF, Cote PJ, Jacob JR, Toshkov IA, Hornbuckle WE, Baldwin BH, et al. Antiviral activity of clevudine [L-FMAU, 1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax). Hepatology 2001;33:254-266.
40. Marcellin P, Mommeja-Marin H, Sacks SL, Lau GK, Sereni D, Bronowicki JP, et al. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 2004;40:140-148.
41. Wang ZX, Fu ZR, Ding GS, Zhang JJ, Fu H, Zhang M, et al. Prevention of hepatitis B virus reinfection after orthotopic liver transplantation. Transplant Proc 2004;36:2315-2317.
42. Barcena R, Casanovas T, Prieto M, Buti M, Moreno JM, Cuervas V, et al. Preliminary data for the treatment of adefovir in transplant patients with hepatitis B resistent to lamvudine. J Hepatol 2004;40(Suppl):38.